Vol. 21/No. 14 | Oncology Live®

July 21, 2020

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

July 21, 2020

Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma

July 20, 2020

A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.

July 19, 2020

A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.

July 18, 2020

Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.

July 16, 2020

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

July 16, 2020

Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.

July 15, 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

July 15, 2020

Thomas E. Stinchcombe, MD, discusses brigatinib’s mechanism as well as the next steps to advance the treatment paradigm for patients with ALK-positive NSCLC.

July 14, 2020

Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.

July 14, 2020

These are disquieting times for clear and decisive messaging regarding vaccines.